IDH2 and acute myeloid leukemia: Activity of enasidenib was verified in vitro via measurement of 2-hydroxy-glutarate (2-HG) levels in IDH2-wild-type (WT) and -mutant (MUT) expressing human erythroid leukemia (HEL) cell lines (Supplementary Figure 8a) and primary AML (Supplementary Figure 8b, Y029, Y031).